Special Issue "Role of PPARs in Neurological and Psychiatric Disorders"
A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Chemical Biology".
Deadline for manuscript submissions: closed (28 February 2023) | Viewed by 4781
Special Issue Editor
Interests: PPAR ligands; CNS disorders; neuroinflammation; mitochondrial disfunction
Special Issue Information
Dear Colleagues,
Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that regulate gene expression by binding to specific peroxisome proliferator response elements on responsive genes. Three isoforms of PPARs have been identified (PPAR-α, PPAR-γ, and PPAR-β/δ), all of which are involved in an array of molecular steps that regulate metabolism and inflammation. Recently, evidence of the roles that PPARs play in central nervous system (CNS) functions has emerged. Preclinical studies, performed on experimental models of different neurological/neurodegenerative, neurodevelopmental, and psychiatric disorders, and a limited number of clinical studies suggest that PPARs may represent promising therapeutic targets for CNS diseases. For disorders such as Alzheimer’s disease, Parkinson’s disease, epilepsy, and autism spectrum disorders, but also for major depression and substance abuse, the available therapeutic tools are often still unsatisfactory, and there is an urgent need for advances in neuropsychopharmacology research that usher in the development of novel therapeutic strategies.
This Special Issue of Biomolecules is dedicated to PPAR and their endogenous and synthetic ligands, with the goal of providing an up-to-date view of the role of the PPAR system in the pathophysiology and treatment of psychiatric, developmental, and neurodegenerative disorders that may lead to the identification and development of effective novel therapeutic agents. Colleagues from different fields are invited to submit original research articles, reviews, or perspective articles on all aspects related to the involvement of the PPAR system in the healthy and diseased brain.
Dr. Maria Graziella De Montis
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2300 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- PPAR ligands
- CNS disorders
- neuroinflammation
- mitochondrial disfunction